ENTITY
BeiGene

BeiGene (BGNE US)

131
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
bullishNetEase Inc
02 Jun 2020 01:13

NetEase Secondary Listing: HK-ADS Premium/(Discount) Views

NetEase Inc (NTES US) has launched a $2.6 billion secondary listing in Hong Kong. This raise would be Hong Kong's biggest stock offering of the...

Logo
416 Views
Share
24 May 2020 16:54

Burning Rock Biotech IPO Initiation: Burning Ambitions

Burning Rock Biotech (BNR US) is a precision oncology and early cancer detection company. It is China’s number one NGS-based cancer therapy...

Logo
286 Views
Share
bullishNetEase Inc
05 May 2020 18:43

NetEase HK Listing - Early Look - Follow the Leader

NetEase Inc (NTES US) has filed confidentially for a secondary listing in Hong Kong, as per media reports. It aims to raise around US$1-2bn. In our...

Logo
489 Views
Share
29 Apr 2020 11:19

JD.com HK Listing - Early Look - Getting the Ball Rolling

IFR announced overnight that JD.com Inc (ADR) (JD US) has filed confidentially for a secondary listing in Hong Kong. The deal is expected to be...

Logo
563 Views
Share
21 Mar 2020 21:00

InnoCare Pharma: Trading Debut, Valuation Scenario Analysis

InnoCare Pharma Ltd (9969 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
338 Views
Share
x